Multicentric carpo-tarsal osteolysis with or without nephropathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2774OMIM:166300M89.5
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Multicentric carpo-tarsal osteolysis with or without nephropathy (also known as multicentric osteolysis, nodulosis, and arthropathy, or MONA; idiopathic multicentric osteolysis; or hereditary multicentric osteolysis) is a rare skeletal disorder characterized by progressive destruction (osteolysis) of the carpal bones (wrist) and tarsal bones (ankle), often beginning in early childhood. The condition primarily affects the musculoskeletal system, leading to pain, swelling, and progressive loss of bone in the hands and feet, which can result in significant functional impairment and deformity. Joint contractures, osteoporosis, and subcutaneous nodules may also develop. In many patients, the disease is accompanied by a progressive nephropathy (kidney disease) that can lead to proteinuria and, in severe cases, end-stage renal failure. The condition is caused by mutations in the MAFB gene, which encodes a transcription factor involved in bone and kidney development. The skeletal manifestations typically present in early childhood, with wrist and ankle swelling being among the first signs noticed by families. Radiographic imaging reveals progressive osteolysis of the carpal and tarsal bones, and in some cases, other bones may also be affected. Kidney involvement varies in severity and may not be present in all affected individuals, hence the designation 'with or without nephropathy.' There is currently no cure for multicentric carpo-tarsal osteolysis. Treatment is primarily supportive and symptomatic, focusing on pain management, physical therapy to maintain joint function, orthopedic interventions for skeletal deformities, and nephrology care for those with kidney involvement. Renal transplantation may be necessary in patients who progress to end-stage kidney disease. Regular monitoring of kidney function is recommended for all affected individuals. Bisphosphonates and anti-inflammatory medications have been tried with variable results.

Also known as:

Clinical phenotype terms— hover any for plain English:

Wrist swellingHP:0001225Carpal osteolysisHP:0001495Metacarpal osteolysisHP:0001504Slender long boneHP:0003100
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Multicentric carpo-tarsal osteolysis with or without nephropathy.

View clinical trials →

No actively recruiting trials found for Multicentric carpo-tarsal osteolysis with or without nephropathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Multicentric carpo-tarsal osteolysis with or without nephropathy community →

No specialists are currently listed for Multicentric carpo-tarsal osteolysis with or without nephropathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Multicentric carpo-tarsal osteolysis with or without nephropathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Multicentric carpo-tarsal osteolysis with or without nephropathyForum →

No community posts yet. Be the first to share your experience with Multicentric carpo-tarsal osteolysis with or without nephropathy.

Start the conversation →

Latest news about Multicentric carpo-tarsal osteolysis with or without nephropathy

No recent news articles for Multicentric carpo-tarsal osteolysis with or without nephropathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Multicentric carpo-tarsal osteolysis with or without nephropathy

What is Multicentric carpo-tarsal osteolysis with or without nephropathy?

Multicentric carpo-tarsal osteolysis with or without nephropathy (also known as multicentric osteolysis, nodulosis, and arthropathy, or MONA; idiopathic multicentric osteolysis; or hereditary multicentric osteolysis) is a rare skeletal disorder characterized by progressive destruction (osteolysis) of the carpal bones (wrist) and tarsal bones (ankle), often beginning in early childhood. The condition primarily affects the musculoskeletal system, leading to pain, swelling, and progressive loss of bone in the hands and feet, which can result in significant functional impairment and deformity. Joi

How is Multicentric carpo-tarsal osteolysis with or without nephropathy inherited?

Multicentric carpo-tarsal osteolysis with or without nephropathy follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Multicentric carpo-tarsal osteolysis with or without nephropathy typically begin?

Typical onset of Multicentric carpo-tarsal osteolysis with or without nephropathy is childhood. Age of onset can vary across affected individuals.